Nature Communications (Aug 2022)
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1
- Hsiao-Yun Chen,
- Yavuz T. Durmaz,
- Yixiang Li,
- Amin H. Sabet,
- Amir Vajdi,
- Thomas Denize,
- Emily Walton,
- Yasmin Nabil Laimon,
- John G. Doench,
- Navin R. Mahadevan,
- Julie-Aurore Losman,
- David A. Barbie,
- Michael Y. Tolstorukov,
- Charles M. Rudin,
- Triparna Sen,
- Sabina Signoretti,
- Matthew G. Oser
Affiliations
- Hsiao-Yun Chen
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- Yavuz T. Durmaz
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- Yixiang Li
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- Amin H. Sabet
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- Amir Vajdi
- Department of Informatics and Analytics, Dana-Farber Cancer Institute
- Thomas Denize
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Emily Walton
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Yasmin Nabil Laimon
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- John G. Doench
- Broad Institute of MIT and Harvard
- Navin R. Mahadevan
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- Julie-Aurore Losman
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- David A. Barbie
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- Michael Y. Tolstorukov
- Department of Informatics and Analytics, Dana-Farber Cancer Institute
- Charles M. Rudin
- Memorial Sloan Kettering Cancer Center
- Triparna Sen
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Sabina Signoretti
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Matthew G. Oser
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-022-31998-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 22
Abstract
LSD1 inhibition blocks the neuroendocrine phenotype of some small cell lung cancers (SCLCs). Here, a genome-wide CRISPR/Cas9 LSD1 inhibitor resistance screen identifies the mRNA-binding protein ZFP36L1 as a gene repressed by LSD1 that when restored inhibits SCLC neuroendocrine differentiation.
